🌱Emerging

Cagrilintide

Also known as: AM833, NN9838, CagriSema

Weight LossHealth
Not FDA Approved

Primary recreational use: Weight loss and obesity management

What is Cagrilintide?

Cagrilintide is a synthetic analog of amylin, developed by Novo Nordisk to target obesity. It's used primarily for weight loss and diabetes management, working as a dual amylin and calcitonin receptor agonist. Currently in Phase 3 clinical trials, it has shown substantial promise but remains unapproved by the FDA. Key risks include gastrointestinal side effects, especially during dose escalation phases.

Primary Benefits

Reduces appetite. Promotes weight loss. Improves glycemic control.

How It Works

Cagrilintide mimics amylin by activating amylin and calcitonin receptors in the brainstem, enhancing satiety and reducing appetite. It acts on both homeostatic and hedonic centers of the brain to promote earlier meal termination and slow gastric emptying, prolonging fullness.

Safety Tips

Precautions reported in community discussions and literature. This is not a complete list.

  • 1.DON'T start with a high dose - begin with a low dose and escalate gradually to reduce side effects.
  • 2.DON'T use if you have a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • 3.DON'T store vials at room temperature; freeze them at -20°C for optimal stability.
  • 4.DON'T ignore signs of fibril formation in the solution; discard cloudy solutions immediately.
  • 5.DON'T administer without rotating injection sites to prevent site reactions.

Who Should NOT Use

  • Medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • Severe gastrointestinal disorders
  • Pregnancy and breastfeeding
  • Severe renal impairment (eGFR <30 mL/min/1.73 m²)

Use Contexts

Different purposes have different protocols, dosing, and considerations

🔬Investigational

Weight Loss

strong evidence

Cagrilintide is being studied for its potential to significantly reduce body weight in individuals with obesity when used alone or in combination with semaglutide.

Evidence: Phase 3 trials demonstrate up to 22.7% weight loss in combination with semaglutide, and 11.8% with monotherapy over 68 weeks.

The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.

Reported Range
1-2.4 mg
Reported Frequency
once weekly
Reported Cycle
17-17 weeks
Reported Route
Subcutaneous

Timing: Flexible but consistent day each week

Notes: Begin with lower doses to minimize gastrointestinal side effects.

Community-Reported Protocols

Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.

Reported GoalReported DoseReported FrequencyReported Route
Weight Loss Monotherapy2.4 mgOnce weeklySubcutaneous injection
Weight Loss Combination (CagriSema)2.4 mg + semaglutide 2.4 mgOnce weeklySubcutaneous injection, abdomen
Dose Escalation Protocol0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mgWeekly increases over 16 weeksSubcutaneous injection

Pharmacokinetics

Half-Life
7.5 days
Time to Peak
2 days
Clearance
~37.5 days

Reported Side Effects

This is not a complete list. Other side effects may occur.

Common
Nauseavery common (>10%)
Injection site reactionsvery common (>10%)
Vomitingcommon (1-10%)
Diarrheacommon (1-10%)
Serious / Rare
  • Acute cholelithiasis (gallstones)
Injection-Specific Warnings
  • Rotate injection sites to prevent localized reactions. Avoid contaminated or cloudy solutions.

Storage

Temperature
Frozen at -20°C
Reconstituted
Refrigerated (2-8°C)
Shelf Life
Reconstitute within 30 days
Light Sensitive
Yes - protect from light
🔬Investigational

Type 2 Diabetes Management

strong evidence

Cagrilintide is used in combination with semaglutide to improve glycemic control alongside weight loss in Type 2 Diabetes management.

Evidence: Phase 3 trials have shown improved glycemic outcomes and significant weight loss.

The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.

Reported Range
1-2.4 mg
Reported Frequency
once weekly
Reported Cycle
17-17 weeks
Reported Route
Subcutaneous

Timing: Consistent day each week

Notes: Combining with metformin or SGLT2 inhibitors can enhance outcomes.

Community-Reported Protocols

Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.

Reported GoalReported DoseReported FrequencyReported Route
Diabetes Management2.4 mg + semaglutide 2.4 mgOnce weeklySubcutaneous injection

Pharmacokinetics

Half-Life
7.5 days
Time to Peak
2 days
Clearance
~37.5 days

Reported Side Effects

This is not a complete list. Other side effects may occur.

Common
Nauseavery common (>10%)
Injection site reactionsvery common (>10%)
Vomitingcommon (1-10%)
Diarrheacommon (1-10%)
Serious / Rare
  • Acute cholelithiasis (gallstones)
Injection-Specific Warnings
  • Rotate injection sites to prevent localized reactions. Avoid contaminated or cloudy solutions.

Storage

Temperature
Frozen at -20°C
Reconstituted
Refrigerated (2-8°C)
Shelf Life
Reconstitute within 30 days
Light Sensitive
Yes - protect from light

Harm Reduction Information

Quality Concerns

  • Potential for fibril formation at neutral pH
  • Contamination risk during reconstitution

Safety Tips

  • Use sterile technique for injections.
  • Rotate injection sites to prevent irritation.
  • Start with lower doses to assess tolerance.
  • Slowly reconstitute to avoid fibril formation.

Warning Signs to Stop

  • Severe nausea or vomiting
  • Persistent gastrointestinal distress
  • Signs of fibril formation in solution
  • Unexplained acute abdominal pain

Seek Medical Help Immediately If

  • Severe allergic reactions
  • Symptoms of acute cholelithiasis
  • Persistent vomiting or dehydration

Frequently Asked Questions

Common questions about Cagrilintide

How long until I see effects?

Cagrilintide typically begins to show effects within 1-2 weeks, with significant weight loss observed over 4-12 weeks.

What time of day should I take it?

Cagrilintide can be taken at any consistent time weekly, though evening injections may reduce morning nausea.

How can I minimize side effects?

To minimize side effects of Cagrilintide, escalate doses slowly and consider evening injections to manage nausea.

Does tolerance develop?

There is no significant tolerance development noted with Cagrilintide, but monitoring and adherence to dosing protocols are required.

How should I store it?

Cagrilintide should be stored frozen at -20°C and protected from light. After reconstitution, keep the solution refrigerated.

Do I need to cycle it?

Cagrilintide is used continuously for optimal efficacy, with no required cycling.

Reported Combinations

Compounds reported to be used alongside Cagrilintide in community discussions

investigational

Semaglutide

Enhances weight loss and glycemic control.

investigational

Metformin

Improves blood sugar control when used alongside Cagrilintide.

investigational

Tirzepatide

Potential complementary effects in diabetes management.

Reported Interactions

Interactions reported in literature and community discussions.

Oral contraceptivesminor

May require timing to avoid interaction.

SGLT2 inhibitorsmoderate

Compatible, but monitor combination use for blood sugar control.

Insulinmoderate

Compatible with monitoring.

Metforminminor

Often combined for enhanced glycemic control.

Pramlintidemajor

Avoid combination due to overlapping amylin pathways.

Reconstitution Calculator

mL
U100 insulin syringe01020304050607080901001mL

100 units = 1 mL

Safety Tips

  • Always consult a licensed medical professional for dosing and reconstitution instructions.
  • Always double check your units. Mixing up mg and mcg can be very dangerous.
  • Make sure to select your syringe type. U-100 and U-50 syringes have different units.
  • Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.

This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.

Explore More Research

Browse our database of peptide research information compiled from published literature and community sources.

Browse All PeptidesAbout Pepbase App

Citations

Last updated: October 18, 2023

Important Disclaimer

AI-Generated Content Notice

The information on this page has been compiled using artificial intelligence (AI) and large language model (LLM) technology from multiple sources including published literature, online communities, and public databases. This content may contain errors, inaccuracies, outdated information, or omissions. We make no guarantees regarding the accuracy, completeness, or reliability of any information presented. You are solely responsible for independently verifying any information before relying on it.

Not Medical Advice

Nothing on this website constitutes medical advice, diagnosis, or treatment recommendations. The information provided is for educational and harm-reduction purposes only. We do not provide individualized dosing guidance or treatment recommendations. Protocols and dosing information shown represent reports from community discussions and published literature—they are not endorsements or recommendations. Always consult with a licensed healthcare professional before making any health-related decisions.

No Endorsement of Use

Pepbase does not endorse, encourage, or recommend the use of any peptide or substance discussed on this website. Many compounds discussed are not approved for human use by the FDA or other regulatory agencies. Some substances may be illegal to possess, sell, or use in your jurisdiction. We do not facilitate or encourage the procurement, distribution, or use of controlled or prescription-only substances. Users are solely responsible for understanding and complying with all applicable laws in their jurisdiction.

Calculators and Tools

Any calculators, estimators, or tools provided on this website are for informational purposes only and produce estimates that may be inaccurate. Errors in calculations can result in serious harm. You are solely responsible for verifying all calculations independently. These tools do not account for individual factors that may affect dosing and should never be relied upon as a substitute for professional medical guidance.

Assumption of Risk

By using this website, you acknowledge that you understand the risks associated with using unregulated substances and that you assume full responsibility for your own health decisions. Pepbase, its creators, contributors, and affiliates disclaim all liability for any harm, injury, or damages arising from the use or misuse of information on this website. Use of any information on this site is entirely at your own risk.

If you are experiencing a medical emergency, call emergency services immediately. If you have questions about medications or supplements, consult a licensed pharmacist or physician.